Literature DB >> 24201308

The 2-methoxy methyl analogue of salvinorin A attenuates cocaine-induced drug seeking and sucrose reinforcements in rats.

Aashish S Morani1, Amy Ewald, Katherine M Prevatt-Smith, Thomas E Prisinzano, Bronwyn M Kivell.   

Abstract

κ Opioid receptor activation by traditional arylacetamide agonists and the novel neoclerodane diterpene κ opioid receptor agonist Salvinorin A (Sal A) results in attenuation of cocaine-seeking behavior in pre-clinical models of addiction. However, adverse effects such as sedation, depression and aversion limit their clinical utility. The Sal A analogue, 2-methoxy-methyl salvinorin B (MOM Sal B) is a longer acting Sal A analogue with high affinity for κ opioid receptors. In this study, we tested MOM Sal B for its ability to modulate cocaine-seeking behavior in rats. MOM Sal B (0.3mg/kg) successfully attenuated cocaine-seeking but also attenuated sucrose reinforcement. No change in activity was observed in either cocaine-induced hyperactivity or spontaneous open field activity tests but increased immobility and decreased swimming times in the forced swim test were observed. This study indicates that κ opioid receptor activation by more potent Sal A analogues modulates cocaine-seeking behavior non-selectively without causing sedation, suggesting an improved side effects profile. However, pro-depressive effects are seen, which may limit the therapeutic potential of this compound. Future studies with Sal A analogues having affinities at other opioid receptors are warranted as they have the potential to identify compounds having effective anti-addiction properties.
© 2013 Published by Elsevier B.V.

Entities:  

Keywords:  Cocaine; Forced swim test; Locomotion; Salvinorin A; Self-administration; Sucrose reinforcement

Mesh:

Substances:

Year:  2013        PMID: 24201308      PMCID: PMC3899895          DOI: 10.1016/j.ejphar.2013.10.050

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  48 in total

1.  Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.

Authors:  Cécile Béguin; Justin Potuzak; Wei Xu; Lee-Yuan Liu-Chen; John M Streicher; Chad E Groer; Laura M Bohn; William A Carlezon; Bruce M Cohen
Journal:  Bioorg Med Chem Lett       Date:  2011-12-07       Impact factor: 2.823

2.  Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates.

Authors:  Matthew D Schmidt; Mark S Schmidt; Eduardo R Butelman; Wayne W Harding; Kevin Tidgewell; Daryl J Murry; Mary Jeanne Kreek; Thomas E Prisinzano
Journal:  Synapse       Date:  2005-12-01       Impact factor: 2.562

3.  Kappa opioid inhibition of morphine and cocaine self-administration in rats.

Authors:  S D Glick; I M Maisonneuve; J Raucci; S Archer
Journal:  Brain Res       Date:  1995-05-29       Impact factor: 3.252

Review 4.  Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments.

Authors:  Mary Jeanne Kreek; Gavin Bart; Charles Lilly; K Steven LaForge; David A Nielsen
Journal:  Pharmacol Rev       Date:  2005-03       Impact factor: 25.468

5.  Effects of the mixed-action kappa/mu opioid agonist 8-carboxamidocyclazocine on cocaine- and food-maintained responding in rhesus monkeys.

Authors:  Glenn W Stevenson; Mark P Wentland; Jean M Bidlack; Nancy K Mello; S Stevens Negus
Journal:  Eur J Pharmacol       Date:  2004-12-15       Impact factor: 4.432

6.  Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.

Authors:  Yulin Wang; Kang Tang; Saadet Inan; Daniel Siebert; Ulrike Holzgrabe; David Y W Lee; Peng Huang; Jian-Guo Li; Alan Cowan; Lee-Yuan Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2004-09-21       Impact factor: 4.030

7.  The kappa-opioid receptor agonist U-69593 attenuates cocaine-induced behavioral sensitization in the rat.

Authors:  C A Heidbreder; S R Goldberg; T S Shippenberg
Journal:  Brain Res       Date:  1993-07-09       Impact factor: 3.252

8.  Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats.

Authors:  Mark S Todtenkopf; Jacqueline F Marcus; Philip S Portoghese; William A Carlezon
Journal:  Psychopharmacology (Berl)       Date:  2004-01-16       Impact factor: 4.530

9.  Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations.

Authors:  Charles Chavkin; Sumit Sud; Wenzhen Jin; Jeremy Stewart; Jordan K Zjawiony; Daniel J Siebert; Beth Ann Toth; Sandra J Hufeisen; Bryan L Roth
Journal:  J Pharmacol Exp Ther       Date:  2004-01-08       Impact factor: 4.030

10.  Exposure to the selective kappa-opioid receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats.

Authors:  Elena H Chartoff; David Potter; Diane Damez-Werno; Bruce M Cohen; William A Carlezon
Journal:  Neuropsychopharmacology       Date:  2008-01-09       Impact factor: 7.853

View more
  8 in total

1.  Semisynthesis and Kappa-Opioid Receptor Activity of Derivatives of Columbin, a Furanolactone Diterpene.

Authors:  Anil Yilmaz; Rachel Saylor Crowley; Alexander M Sherwood; Thomas E Prisinzano
Journal:  J Nat Prod       Date:  2017-07-18       Impact factor: 4.050

2.  MP1104, a mixed kappa-delta opioid receptor agonist has anti-cocaine properties with reduced side-effects in rats.

Authors:  Diana V Atigari; Rajendra Uprety; Gavril W Pasternak; Susruta Majumdar; Bronwyn M Kivell
Journal:  Neuropharmacology       Date:  2019-02-13       Impact factor: 5.250

3.  Modular Approach to pseudo-Neoclerodanes as Designer κ-Opioid Ligands.

Authors:  Alexander M Sherwood; Samuel E Williamson; Rachel S Crowley; Logan M Abbott; Victor W Day; Thomas E Prisinzano
Journal:  Org Lett       Date:  2017-09-14       Impact factor: 6.005

4.  The C-2 derivatives of salvinorin A, ethoxymethyl ether Sal B and β-tetrahydropyran Sal B, have anti-cocaine properties with minimal side effects.

Authors:  Amy W M Ewald; Peter J Bosch; Aimee Culverhouse; Rachel Saylor Crowley; Benjamin Neuenswander; Thomas E Prisinzano; Bronwyn M Kivell
Journal:  Psychopharmacology (Berl)       Date:  2017-05-23       Impact factor: 4.530

5.  Pharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A.

Authors:  B Simonson; A S Morani; A W M Ewald; L Walker; N Kumar; D Simpson; J H Miller; T E Prisinzano; B M Kivell
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

6.  Kappa Opioid Receptor Agonist Mesyl Sal B Attenuates Behavioral Sensitization to Cocaine with Fewer Aversive Side-Effects than Salvinorin A in Rodents.

Authors:  Bronwyn M Kivell; Kelly F Paton; Nitin Kumar; Aashish S Morani; Aimee Culverhouse; Amy Shepherd; Susan A Welsh; Andrew Biggerstaff; Rachel S Crowley; Thomas E Prisinzano
Journal:  Molecules       Date:  2018-10-11       Impact factor: 4.411

Review 7.  Pharmacokinetics and Pharmacodynamics of Salvinorin A and Salvia divinorum: Clinical and Forensic Aspects.

Authors:  Andreia Machado Brito-da-Costa; Diana Dias-da-Silva; Nelson G M Gomes; Ricardo Jorge Dinis-Oliveira; Áurea Madureira-Carvalho
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-03

8.  The Salvinorin Analogue, Ethoxymethyl Ether Salvinorin B, Promotes Remyelination in Preclinical Models of Multiple Sclerosis.

Authors:  Kelly F Paton; Katharina Robichon; Nikki Templeton; Lisa Denny; Afnan Al Abadey; Dan Luo; Thomas E Prisinzano; Anne C La Flamme; Bronwyn M Kivell
Journal:  Front Neurol       Date:  2021-12-20       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.